**Note: timings are in EDT**

  1. Welcome and introduction

    Chemical Watch

  2. Session one: Regulatory updates
  3. Keynote  Keynote: TSCA Updates from the EPA

    Alexandra Dunn Alexandra Dunn
    Assistant Administrator - Office of Chemical Safety and Pollution Prevention, U.S. Environmental Protection Agency
  4. Chemical data reporting (CDR) 2020: Something old, something new

    • Update on the current reporting window
    • Update on the small business definition
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States
  5. TSCA fees

    • Upcoming rulemaking on fee exemptions
    • Overview of self-identification process
    • Strategies for payment: How are consortia dividing up fees between participants?
    Lynn L. Bergeson Lynn L. Bergeson
    Managing Partner, Bergeson & Campbell, United States
  6. Q&A

  7. TSCA new chemical programme

    • Update on the new chemicals decision-making framework
    • Significant new use rules (Snurs) and their application to address potential concerns with new chemicals
    Stacie Abraham Stacie Abraham
    regulatory program manager, Innovation & Client Solutions / TSCA ServicesTeam Lead, UL
  8. TSCA new chemical programme statistics and pre-manufacture notice (PMN) status

    • Programme statistics: update on PMN 'backlog' and EPA new chemical review efforts
    • A reflection on PMN submissions since the new higher fees took effect
    Devin Millions
    Managing Scientist, Exponent
  9. Q&A

  10. Break

  11. Risk management and evaluation
  12. A reflection on recent risk evaluations: NGO perspective

    Is the EPA risk evaluation process effectively protecting the public?

    • The impact of the SACC peer review process
    • Gaps in the EPA evaluations
    • Important policy and legal issues
    Robert M. Sussman Robert M. Sussman
    Counsel, Safer Chemicals Healthy Families,, and Principal, Sussman and Associates, United States
  13. Preview of emerging issues on the next 20 risk evaluations: Lessons learned from the first 10

    • Should we expect the EPA to issue test orders and make other efforts to fill data gaps? 
    • What role are industry consortia playing in this process?

    Speaker from Keller and Heckman LLP, US

  14. Risk management for chemicals under TSCA: An industry perspective

    • A review of the rule to manage certain persistent, bioaccumulative and toxic (PBT) chemicals
    • Looking ahead to the rulemakings for the first ten chemicals subject to risk evaluation

    Speaker to be confirmed

  15. Q&A

  16. Session three: Confidential business information (CBI) under TSCA
  17. CBI substantiation overview

    • Issues that could cause the EPA to drop a chemical identity confidentiality claim and what recourse companies have to stop this
    • An insight into CBI’s upfront substantiation requirements
    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP
  18. Q&A

  19. Session four: Enforcement and litigation
  20. Enforcement and litigation issues including enforcement during the Covid-19 pandemic

    Sara Beth Watson Sara Beth Watson
    Counsel, Steptoe and Johnson LLP
  21. Q&A

  22. Virtual coffee break and networking

  23. Session five: Stakeholder perspectives and outlooks
  24. Covid 19 – the impact of the coronavirus on TSCA

    Kate Sellers
    Technical Director - North America, ERM
  25. Reflections on four years of implementing the Lautenberg Amendments: a former EPA insider’s perspective and advice

    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP
  26. Stakeholder panel: A look to the future

    Speakers from:

    • Bergeson and Campbell
    • knoell USA
    • ERM
    • Chemical Watch
    Richard Engler, Ph.D. Richard Engler, Ph.D.
    Director of Chemistry, Bergeson & Campbell, P.C.
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States
  27. Q&A and conference wrap-up

    Chemical Watch